Amvuttra
(Vutrisiran)Phase 3RNA therapy
Alnylam PharmaceuticalsVutrisiran is used to treat amyloidosis, an inherited disorder where abnormal proteins accumulate and damage nerves and the heart. This medication works by reducing the production of these harmful proteins in the body.[1] Amvuttra is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Amvuttra is one of 40 small molecule programs targeting Cardiomyopathy. It is currently in Phase 3.
2
Indications
4
Total Trials
3
Active Trials
39
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
10
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
91 competitors in Cardiomyopathy
#DrugCompanyPhaseTrials
1Dobutrex
Eli LillyPhase 3
Plaquenil
Alnylam PharmaceuticalsPhase 3
Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Wainua (autoinjector)
AstraZenecaPhase 3
Immunoglobulins
CSL BehringPhase 3
Cialis
Eli LillyPhase 2
Aldactone
PfizerPhase 2
Cellcept
RochePhase 2
Betaseron
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cardiomyopathy2 trials
Hereditary Transthyretin Amyloidosis2 trials
Regulatory
FDA Approval Timeline[4]
Jun 13, 2022
AMVUTTRA
NDA NDA215515
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vutrisiran. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- RNA therapy[2]
- Highest Phase
- Phase 3[1]
- Company